Skip to Content
 

News: Translational Research and Interventional Oncology Research Program

Pathways of radiosensitization

Thursday, April 25th, 2019

Austin Kirschner, MD, PhD, and colleagues have studied the mechanism of radiation sensitization for enzalutamide using multiple models of human prostate cancer.

Study reframes approach to targeted therapy resistance

Thursday, April 25th, 2019

A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.

Achilles’ heel for kidney cancer

Monday, March 4th, 2019

A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.

Investigators map genomic landscape of very rare cancer

Monday, March 4th, 2019

Vanderbilt researchers have mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

New algorithm calculates drug synergy; initial tests involve melanoma, lung cancer

Monday, February 25th, 2019

Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team for calculating drug synergy.

AHA statement supports vascular cardio-oncology

Monday, February 25th, 2019

The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.

Discovery points to new cancer immunotherapy option

Monday, February 25th, 2019

Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Research explores link between stem cell transplant, diabetes

Friday, January 18th, 2019

As many as 50 percent of stem cell transplant recipients develop diabetes. Brian Engelhardt, M.D., and an interdisciplinary team of experts in diabetes, immunology, endocrine surgery and transplantation are determined to understand why.

Grant to help address complexity of cancer care

Wednesday, January 16th, 2019

Jeremy Warner, MD, MS, associate professor of Medicine and Biomedical Informatics, has been awarded a $1 million grant from the National Cancer Institute to develop software that will help clinicians keep up with the increasing complexity of cancer care.

Lung cancer survival signal

Saturday, December 1st, 2018

A recent study shows that a cell receptor, SSTR2, is a candidate biomarker for poor prognosis and a potential therapeutic target for small cell lung cancer.

Next Page »